PMID- 36764021
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230328
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
VI  - 66
DP  - 2023 Mar
TI  - The impact of immunopeptidomics: From basic research to clinical implementation.
PG  - 101727
LID - S1044-5323(23)00018-0 [pii]
LID - 10.1016/j.smim.2023.101727 [doi]
AB  - The immunopeptidome is the set of peptides presented by the major 
      histocompatibility complex (MHC) molecules, in humans also known as the human 
      leukocyte antigen (HLA), on the surface of cells that mediate T-cell 
      immunosurveillance. The immunopeptidome is a sampling of the cellular proteome 
      and hence it contains information about the health state of cells. The peptide 
      repertoire is influenced by intra- and extra-cellular perturbations - such as in 
      the case of drug exposure, infection, or oncogenic transformation. 
      Immunopeptidomics is the bioanalytical method by which the presented peptides are 
      extracted from biological samples and analyzed by high-performance liquid 
      chromatography coupled to tandem mass spectrometry (MS), resulting in a deep 
      qualitative and quantitative snapshot of the immunopeptidome. In this review, we 
      discuss published immunopeptidomics studies from recent years, grouped into three 
      main domains: i) basic, ii) pre-clinical and iii) clinical research and 
      applications. We review selected fundamental immunopeptidomics studies on the 
      antigen processing and presentation machinery, on HLA restriction and studies 
      that advanced our understanding of various diseases, and how exploration of the 
      antigenic landscape allowed immune targeting at the pre-clinical stage, paving 
      the way to pioneering exploratory clinical trials where immunopeptidomics is 
      directly implemented in the conception of innovative treatments for cancer 
      patients.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Shapiro, Ilja E
AU  - Shapiro IE
AD  - Ludwig Institute for Cancer Research, University of Lausanne, 1005 Lausanne, 
      Switzerland; Department of Oncology, Centre hospitalier universitaire vaudois 
      (CHUV), 1005 Lausanne, Switzerland; Agora Cancer Research Centre, 1011 Lausanne, 
      Switzerland.
FAU - Bassani-Sternberg, Michal
AU  - Bassani-Sternberg M
AD  - Ludwig Institute for Cancer Research, University of Lausanne, 1005 Lausanne, 
      Switzerland; Department of Oncology, Centre hospitalier universitaire vaudois 
      (CHUV), 1005 Lausanne, Switzerland; Agora Cancer Research Centre, 1011 Lausanne, 
      Switzerland; Center of Experimental Therapeutics, Department of Oncology, Centre 
      hospitalier universitaire vaudois (CHUV), 1005 Lausanne, Switzerland. Electronic 
      address: michal.bassani@chuv.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230208
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (HLA Antigens)
RN  - 0 (Peptides)
SB  - IM
MH  - Humans
MH  - *Histocompatibility Antigens Class I
MH  - *Histocompatibility Antigens Class II
MH  - HLA Antigens
MH  - Antigen Presentation
MH  - Peptides
OTO - NOTNLM
OT  - Antigen Discovery
OT  - Clinical applications
OT  - Immunopeptidomics
OT  - Mass spectrometry
EDAT- 2023/02/11 06:00
MHDA- 2023/03/21 06:00
CRDT- 2023/02/10 18:01
PHST- 2022/11/21 00:00 [received]
PHST- 2023/01/30 00:00 [revised]
PHST- 2023/02/01 00:00 [accepted]
PHST- 2023/02/11 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2023/02/10 18:01 [entrez]
AID - S1044-5323(23)00018-0 [pii]
AID - 10.1016/j.smim.2023.101727 [doi]
PST - ppublish
SO  - Semin Immunol. 2023 Mar;66:101727. doi: 10.1016/j.smim.2023.101727. Epub 2023 Feb 
      8.